SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9
http://www.w3.org/2000/01/rdf-schema#comment
"suppression of Noxa in the lymph node environment contributes to the persistence of B-CLL at these sites and suggest that therapeutic targeting of Noxa might be beneficial"
xsd:string
http://purl.uniprot.org/uniprot/#_49990D552A1EAC59D2D54E215DCD22FB8E93907D5DE4BFB499A2A4CECF3C212CD2F1AC237D8D7587B359572116A6F656
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9
http://purl.uniprot.org/uniprot/A0A0S2Z490
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9
http://purl.uniprot.org/uniprot/#_A0A0S2Z490-mappedCitation-17038534
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C658C9E1F60299B3574D0206F09F97C26CCB5CA354C7B2A28C6EB4CED75EC1F7A700DCD16C6DF83F499C0958BFDC0FA9